Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S., Zonder, Jeffrey, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Bumma, Naresh, Kaufman, Jonathan L., Medvedova, Eva, Kovacsovics, Tibor, Rosenzweig, Michael, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7332897/
https://ncbi.nlm.nih.gov/pubmed/32244252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004460
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak